These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

416 related items for PubMed ID: 26352578

  • 1. Inhibition of cyclin-dependent kinases 4 and 6 in breast cancer.
    Mayer EL.
    Clin Adv Hematol Oncol; 2015 Apr; 13(4):215-7. PubMed ID: 26352578
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. An Update on the Clinical Use of CDK4/6 Inhibitors in Breast Cancer.
    Robert M, Frenel JS, Bourbouloux E, Rigaud DB, Patsouris A, Augereau P, Gourmelon C, Campone M.
    Drugs; 2018 Sep; 78(13):1353-1362. PubMed ID: 30143968
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women.
    Cersosimo RJ.
    Am J Health Syst Pharm; 2019 Aug 01; 76(16):1183-1202. PubMed ID: 31369120
    [Abstract] [Full Text] [Related]

  • 6. Cyclin-dependent kinase 4/6 inhibitors in hormone receptor-positive early breast cancer: preliminary results and ongoing studies.
    Kwapisz D.
    Breast Cancer; 2018 Sep 01; 25(5):506-516. PubMed ID: 29700711
    [Abstract] [Full Text] [Related]

  • 7. Role of cyclin-dependent kinase 4/6 inhibitors in the current and future eras of cancer treatment.
    Parylo S, Vennepureddy A, Dhar V, Patibandla P, Sokoloff A.
    J Oncol Pharm Pract; 2019 Jan 01; 25(1):110-129. PubMed ID: 29726787
    [Abstract] [Full Text] [Related]

  • 8. [CDK4/6 inhibitors: biomarkers, mechanisms of resistance and interest of the study of the circulating tumor DNA].
    Gonçalves A.
    Bull Cancer; 2018 Jun 01; 105(6):545-546. PubMed ID: 29729807
    [No Abstract] [Full Text] [Related]

  • 9. Cyclin-Dependent Kinase 4/6 Inhibitors for the Treatment of Breast Cancer: A Review of Preclinical and Clinical Data.
    Vidula N, Rugo HS.
    Clin Breast Cancer; 2016 Feb 01; 16(1):8-17. PubMed ID: 26303211
    [Abstract] [Full Text] [Related]

  • 10. Cyclin-dependent kinase 4/6 inhibitors as first-line treatment for post-menopausal metastatic hormone receptor-positive breast cancer patients: a systematic review and meta-analysis of phase III randomized clinical trials.
    Ramos-Esquivel A, Hernández-Steller H, Savard MF, Landaverde DU.
    Breast Cancer; 2018 Jul 01; 25(4):479-488. PubMed ID: 29470723
    [Abstract] [Full Text] [Related]

  • 11. Approaching Use of CDK4/6 Inhibitors in Metastatic HR+, HER2- Breast Cancer.
    Weiss J, Afghahi A, Shagisultanova E, Diamond JR.
    Oncology (Williston Park); 2018 Oct 15; 32(10):513-5. PubMed ID: 30334242
    [No Abstract] [Full Text] [Related]

  • 12. Extending indication of cyclin-dependent kinase 4/6 inhibitors in the adjuvant and neoadjuvant setting.
    Criscitiello C, Viale G, Curigliano G.
    Curr Opin Oncol; 2017 Nov 15; 29(6):428-433. PubMed ID: 28872469
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Mechanisms of therapeutic CDK4/6 inhibition in breast cancer.
    Scott SC, Lee SS, Abraham J.
    Semin Oncol; 2017 Dec 15; 44(6):385-394. PubMed ID: 29935900
    [Abstract] [Full Text] [Related]

  • 16. Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells.
    Ogata R, Kishino E, Saitoh W, Koike Y, Kurebayashi J.
    Breast Cancer; 2021 Jan 15; 28(1):206-215. PubMed ID: 32860163
    [Abstract] [Full Text] [Related]

  • 17. Ribociclib (Kisqali) for advanced or metastatic breast cancer.
    Med Lett Drugs Ther; 2017 Oct 23; 59(1532):e178-e179. PubMed ID: 29039822
    [No Abstract] [Full Text] [Related]

  • 18. Abemaciclib (Verzenio)--a third CDK 4/6 inhibitor for breast cancer.
    Med Lett Drugs Ther; 2017 Nov 06; 59(1533):185-186. PubMed ID: 29125595
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Targeting CDK4/6 pathways and beyond in breast cancer.
    Ribnikar D, Volovat SR, Cardoso F.
    Breast; 2019 Feb 06; 43():8-17. PubMed ID: 30359883
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.